Literature DB >> 9846961

T-cell-rich large-B-cell lymphomas contain non-activated CD8+ cytolytic T cells, show increased tumor cell apoptosis, and have lower Bcl-2 expression than diffuse large-B-cell lymphomas.

R E Felgar1, K R Steward, J B Cousar, W R Macon.   

Abstract

The factor(s) responsible for the reduced B cell number and increased T cell infiltrate in T-cell-rich large-B-cell lymphomas (TCRBCLs) have not been well characterized. We studied 18 TCRBCLs and 12 diffuse large-B-cell lymphomas (DLBCLs) to compare the 1) predominant T cell subpopulation(s), 2) expression of cytotoxic granule proteins (TIA-1 and granzyme B), 3) level of tumor cell apoptosis (Apoptag system, Oncor, Gaithersburg, MD), and 4) expression of Ki-67 (Mib-1) and apoptosis-related proteins (fas (CD95), bcl-2, and p53). T cells in TCRBCLs and DLBCLs were predominantly CD8+ T cells expressing alphabeta T-cell receptors and TIA-1 (16 of 18 TCRBCLs with >50% TIA-1+ small lymphocytes) but lacking granzyme B (16 of 18 TCRBCLs with <25% granzyme B+ small lymphocytes). Scattered apoptotic tumor cells (confirmed with CD20 co-labeling) were present in 15 of 18 TCRBCLs, with 14 of 15 cases having <10% apoptotic cells. No apoptotic cells were seen in 12 of 12 DLBCLs. In 16 of 16 immunoreactive TCRBCLs, <25% tumor cells were bcl-2+, whereas 6 of 12 DLBCLs had >50% bcl-2+ tumor cells. CD95 (fas) expression was also lower, with 3 of 18 (16.7%) TCRBCLs versus 4 of 12 (33%) DLBCLs having >25% CD95+ tumor cells. TCRBCLs and DLBCLs had similar levels of p53 and Ki-67 (Mib-1) expression. Thus, T cells in TCRBCLs are non-activated cytotoxic T lymphocytes (TIA-1+, granzyme B-). Tumor cell apoptosis (perhaps cytotoxic T cell mediated) may partly account for the decreased number of large (neoplastic) B cells in TCRBCLs, but other factors (ie, decreased bcl-2 expression) may also be needed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9846961      PMCID: PMC1866338          DOI: 10.1016/S0002-9440(10)65685-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes.

Authors:  P Anderson; C Nagler-Anderson; C O'Brien; H Levine; S Watkins; H S Slayter; M L Blue; S F Schlossman
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

2.  Large B-cell lymphoma rich in T-cells and simulating Hodgkin's disease.

Authors:  S M Chittal; P Brousset; J J Voigt; G Delsol
Journal:  Histopathology       Date:  1991-09       Impact factor: 5.087

3.  A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells.

Authors:  Q Tian; M Streuli; H Saito; S F Schlossman; P Anderson
Journal:  Cell       Date:  1991-11-01       Impact factor: 41.582

Review 4.  Multiple mechanisms of lymphocyte-mediated killing.

Authors:  J D Young; C C Liu
Journal:  Immunol Today       Date:  1988-05

5.  Chromosome abnormalities in poorly differentiated lymphocytic lymphoma.

Authors:  S Fukuhara; J D Rowley; D Variakojis; H M Golomb
Journal:  Cancer Res       Date:  1979-08       Impact factor: 12.701

6.  Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation.

Authors:  M L Cleary; S D Smith; J Sklar
Journal:  Cell       Date:  1986-10-10       Impact factor: 41.582

7.  Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer.

Authors:  J J Yunis; G Frizzera; M M Oken; J McKenna; A Theologides; M Arnesen
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

Review 8.  Relationship of p53 to the control of apoptotic cell death.

Authors:  M Oren
Journal:  Semin Cancer Biol       Date:  1994-06       Impact factor: 15.707

9.  T-cell-rich B-cell lymphoma.

Authors:  A D Ramsay; W J Smith; P G Isaacson
Journal:  Am J Surg Pathol       Date:  1988-06       Impact factor: 6.394

10.  A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.

Authors:  S Yonehara; A Ishii; M Yonehara
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

View more
  7 in total

1.  T-cell-rich large-B-cell lymphoma (TCRBCL) as compared to diffuse large-B-cell lymphoma.

Authors:  J J Oudejans; D F Dukers; R L ten Berge; C J Meijer
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

2.  Intra-tumoral cytolytic cells: pattern of distribution in B-cell non Hodgkin s lymphoma.

Authors:  S Perambakam; K Naresh; A Nerurkar; J Nadkarni
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

3.  Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000.

Authors:  T Mitterlechner; M Fiegl; H Mühlböck; W Oberaigner; S Dirnhofer; A Tzankov
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

4.  T-cell/histiocyte-rich large B-cell lymphoma.

Authors:  Stefania Pittaluga; Elaine S Jaffe
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

Review 5.  Is Hodgkin lymphoma just another B-cell lymphoma?

Authors:  Harald Stein; Roshanak Bob
Journal:  Curr Hematol Malig Rep       Date:  2009-07       Impact factor: 3.952

6.  Identification of FCER1G related to Activated Memory CD4+ T Cells Infiltration by Gene Co-expression Network and Construction of a Risk Prediction Module in Diffuse Large B-Cell Lymphoma.

Authors:  Xiaoyu Xiang; Li-Min Gao; Yuehua Zhang; Yuan Tang; Sha Zhao; Weiping Liu; Yunxia Ye; Wenyan Zhang
Journal:  Front Genet       Date:  2022-05-30       Impact factor: 4.772

7.  T Cell/Histiocyte-Rich Large B Cell Lymphoma of the Thymus: A Diagnostic Pitfall.

Authors:  Jie Xu; Xiaojun Wu; Vishnu Reddy
Journal:  Case Rep Hematol       Date:  2016-01-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.